Drug Trial Radar · NCT07819097
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
May 16, 2027
Study completion May 16, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults. Participants will take part in this study for about 6 months. The study will include people in China and the United States. In China, participants will receive either RSVpreF or placebo. A placebo is a dummy vaccine with no active ingredient, but it looks just like the vaccine being studied. In the United States, all participants will receive RSVpreF. Researchers will check for any reactions. They will also check blood test results to learn how the body responds to the vaccine. The main questions the study aims to answer are: * What local reactions and systemic events (body-wide symptoms) do participants have after a RSVpreF vaccination? * What medical problems do participants have after a RSVpreF vaccination? * Researchers will compare antibody levels from blood tests between the China cohort and the US cohort. An antibody is a substance in the body that try to fight off an infection or foreign substance. Participants will: * Have a screening visit to make sure they qualify for the study (participants in China will have this visit before the day of vaccination) * Receive the RSVpreF vaccination (or a placebo injection if in the China cohort) once at Visit 1. * Have a telephone or clinic visit 1 week later to assess local reactions and systemic events. * Have a clinic visit a month after vaccination for a checkup and tests. * Have a telephone or clinic visit 6 months after vaccination for a health check. * Have a blood test at screening (if in the China cohort only), on the day of vaccination and 1 month after vaccination.
Conditions
- Adult
- Healthy Participants
Interventions
RSVpreFBiological
Single Dose
PlaceboOther
Single Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting local reactions: pain at the injection site, redness, and swellingTime frame: Within 7 days after vaccination
- Percentage of participants reporting systemic events: fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain, and joint painTime frame: Within 7 days after vaccination
- Percentage of participants reporting adverse events (AEs)Time frame: Within 1 month after vaccination
- Percentage of participants reporting serious adverse events (SAEs)Time frame: Through 6 months after vaccination
- Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)Time frame: Through 6 months after vaccination
- RSV A and RSV B neutralizing antibody levels before vaccination and 1 month after vaccinationTime frame: Before vaccination and 1 month after vaccination
- Geometric mean fold rise in RSV A and RSV B neutralizing antibody levels from before vaccination to 1 month after vaccinationTime frame: Before vaccination to 1 month after vaccination
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Headlands Research - Scottsdale
Scottsdale, Arizona · Not yet recruiting
Orange County Research Center
Lake Forest, California · Not yet recruiting
Artemis Institute for Clinical Research
Riverside, California · Not yet recruiting
Clinical Research Consulting, LLC
Milford, Connecticut · Not yet recruiting
George Washington University
Washington D.C., District of Columbia · Not yet recruiting
Solaris Clinical Research
Meridian, Idaho · Not yet recruiting
MediSphere Medical Research Center, LLC
Evansville, Indiana · Not yet recruiting
IMA Clinical Research Warren
Warren Township, New Jersey · Not yet recruiting
Remington-Davis, Inc
Columbus, Ohio · Not yet recruiting
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania · Not yet recruiting
J. Lewis Research, Inc. / Foothill Family Clinic Draper
Draper, Utah · Not yet recruiting
J. Lewis Research, Inc. / Jordan River Family Medicine
South Jordan, Utah · Not yet recruiting
Charlottesville Medical Research Center, LLC
Charlottesville, Virginia · Not yet recruiting
Clinical Research Partners, LLC
Richmond, Virginia · Not yet recruiting
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.